Previous 10 | Next 10 |
Alimera Sciences, Inc. (NASDAQ: ALIM) is one of today's top gainers. The company's shares have moved 75.56% on the day to $5.53. Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internation...
A look at the top 10 most actives in the United States Agrify Corporation (AGFY) rose 164.2% to $0.6658 on volume of 125,460,313 shares NVIDIA Corporation (NVDA) fell 2.9% to $122.88 on volume of 51,163,891 shares Crown Electrokinetics Corp. (CRKN) fell 0.3% to $0.04097 on volume of 44,45...
MONSEY, N.Y., June 24, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”) to ANI Pharmaceuticals (“ANI”) for $5.50 per share in cash, plus a contingent...
2024-06-24 07:23:16 ET More on ANI Pharmaceuticals ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked ANI Pharmaceuticals, Inc. (ANIP) Q1 2024 Earnings Call Transcript ANI Pharmaceuticals Q1 2024 Earnings Preview Seeking Alpha’s Qua...
Conference call scheduled for today at 8:30 a.m. ET Strengthens Rare Disease segment as largest driver of future growth, expected to add approximately $105 million in highly durable branded revenue Adds two commercial assets ILUVIEN ® and YUTIQ &...
2024-05-14 13:40:03 ET Alimera Sciences, Inc. (ALIM) Q1 2024 Earnings Conference Call May 14, 2024 9:00 AM ET Company Participants Scott Gordon - CORE Investor Relations Rick Eiswirth - President and Chief Executive Officer Elliot Maltz - Chief Financial Officer ...
2024-05-14 07:34:18 ET More on Alimera Sciences Seeking Alpha’s Quant Rating on Alimera Sciences Historical earnings data for Alimera Sciences Financial information for Alimera Sciences Read the full article on Seeking Alpha For further details...
Net Revenue up 70% to $23 Million vs. Q1 2023 Global End User Demand Up 23% vs. Q1 2023 Reiterates Improved 2024 Net Revenue and Adjusted EBITDA Guidance ATLANTA, May 14, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global p...
2024-05-13 13:39:39 ET More on Alimera Sciences Alimera Sciences, Inc. (ALIM) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Alimera Sciences Historical earnings data for Alimera Sciences Financial information for Alimera Sciences ...
ATLANTA, May 07, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announced today it ...
News, Short Squeeze, Breakout and More Instantly...
Alimera Sciences Inc. Company Name:
ALIM Stock Symbol:
NASDAQ Market:
Alimera Sciences Inc. Website:
NEW YORK, NY / ACCESSWIRE / July 3, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Perficient, Inc. (NASDAQ:PRFT)'s sal...
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Alimera Sciences, Inc. (NASDAQ:ALIM)'...
2024-06-25 11:30:02 ET Alliance Global Partners analyst issues NEUTRAL recommendation for ALIM on June 25, 2024 10:23AM ET. The previous analyst recommendation was Buy. ALIM was trading at $5.53 at issue of the analyst recommendation. The overall analyst consensus : HOLD...